Remove atypical-big-pharma-vc-pact-gilead-secures-210m-trodelvy-funding-abingworth
article thumbnail

In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials

Fierce Pharma

But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional. Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.

Biopharma 272